A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Nicholas J. Barrows; Rafael K. Campos; Steven T. Powell; K. Reddisiva Prasanth; Geraldine Schott-Lerner; Ruben Soto-Acosta; Gaddiel Galarza-Muñoz; Erica L. McGrath; Rheanna Urrabaz-Garza; Junling Gao; Ping Wu; Ramkumar Menon; George Saade; Ildefonso Fernandez-Salas; Shannan L. Rossi; Nikos Vasilakis; Andrew Routh; Shelton S. Bradrick; Mariano A. Garcia-Blanco

doi:10.1016/j.chom.2016.07.004

A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Nicholas J. Barrows, Rafael K. Campos, Steven T. Powell, K. Reddisiva Prasanth, Geraldine Schott-Lerner, Ruben Soto-Acosta, Gaddiel Galarza-Muñoz, Erica L. McGrath, Rheanna Urrabaz-Garza, Junling Gao, Ping Wu, Ramkumar Menon, George Saade, Ildefonso Fernandez-Salas, Shannan L. Rossi, Nikos Vasilakis, Andrew Routh, Shelton S. Bradrick, Mariano A. Garcia-Blanco

Research output: Contribution to journal › Article › peer-review

401 Scopus citations

Abstract

Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.

Original language	English (US)
Pages (from-to)	259-270
Number of pages	12
Journal	Cell Host and Microbe
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.chom.2016.07.004
State	Published - Aug 10 2016

ASJC Scopus subject areas

Parasitology
Microbiology
Virology

Access to Document

10.1016/j.chom.2016.07.004

Cite this

Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., Wu, P., Menon, R., Saade, G., Fernandez-Salas, I., Rossi, S. L., Vasilakis, N., Routh, A., Bradrick, S. S., & Garcia-Blanco, M. A. (2016). A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host and Microbe, 20(2), 259-270. https://doi.org/10.1016/j.chom.2016.07.004

Barrows, NJ, Campos, RK, Powell, ST, Prasanth, KR, Schott-Lerner, G, Soto-Acosta, R, Galarza-Muñoz, G, McGrath, EL, Urrabaz-Garza, R, Gao, J, Wu, P , Menon, R, Saade, G, Fernandez-Salas, I, Rossi, SL , Vasilakis, N, Routh, A, Bradrick, SS & Garcia-Blanco, MA 2016, 'A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection', Cell Host and Microbe, vol. 20, no. 2, pp. 259-270. https://doi.org/10.1016/j.chom.2016.07.004

@article{161b32ca48514ffea5e3b6cf27f2b880,

title = "A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection",

abstract = "Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.",

author = "Barrows, {Nicholas J.} and Campos, {Rafael K.} and Powell, {Steven T.} and Prasanth, {K. Reddisiva} and Geraldine Schott-Lerner and Ruben Soto-Acosta and Gaddiel Galarza-Mu{\~n}oz and McGrath, {Erica L.} and Rheanna Urrabaz-Garza and Junling Gao and Ping Wu and Ramkumar Menon and George Saade and Ildefonso Fernandez-Salas and Rossi, {Shannan L.} and Nikos Vasilakis and Andrew Routh and Bradrick, {Shelton S.} and Garcia-Blanco, {Mariano A.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = aug,

day = "10",

doi = "10.1016/j.chom.2016.07.004",

language = "English (US)",

volume = "20",

pages = "259--270",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

AU - Barrows, Nicholas J.

AU - Campos, Rafael K.

AU - Powell, Steven T.

AU - Prasanth, K. Reddisiva

AU - Schott-Lerner, Geraldine

AU - Soto-Acosta, Ruben

AU - Galarza-Muñoz, Gaddiel

AU - McGrath, Erica L.

AU - Urrabaz-Garza, Rheanna

AU - Gao, Junling

AU - Wu, Ping

AU - Menon, Ramkumar

AU - Saade, George

AU - Fernandez-Salas, Ildefonso

AU - Rossi, Shannan L.

AU - Vasilakis, Nikos

AU - Routh, Andrew

AU - Bradrick, Shelton S.

AU - Garcia-Blanco, Mariano A.

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.

AB - Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84979738780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979738780&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2016.07.004

DO - 10.1016/j.chom.2016.07.004

M3 - Article

C2 - 27476412

AN - SCOPUS:84979738780

SN - 1931-3128

VL - 20

SP - 259

EP - 270

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 2

ER -

A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this